IBA’s Proteus®ONE selected by Advocate Radiation Oncology for new proton therapy center in Florida
07 April 2021 - 06:00PM
IBA’s Proteus®ONE selected by Advocate Radiation Oncology for new
proton therapy center in Florida
Louvain-La-Neuve, Belgium, April 07,
2021 – IBA(Ion Beam Applications S.A., EURONEXT),
the world’s leading provider of proton therapy solutions for the
treatment of cancer, today announces that its Proteus®ONE1
compact proton therapy solution has been selected by Advocate
Radiation Oncology in conjunction with its affiliate
Southwest Florida Proton for its new radiation oncology
center. The site will serve the greater population of Southwest
Florida in a centralized location between Lee and Collier
County.
The parties have signed a binding term sheet for
the delivery of IBA’s Proteus®ONE solution
including Pencil Beam Scanning (PBS), and a fully integrated
quality assurance (QA) hardware and software package from IBA
Dosimetry America, Inc. The term sheet includes long-term operation
and maintenance services to be provided by IBA. Advocate Radiation
Oncology expects to start treating patients by 2023. The typical
end-user price for a Proteus®ONE system with a 10-year maintenance
contract usually ranges between 40 and 50 million US dollars. Both
parties will be working diligently to complete negotiations of the
final agreement in the coming months. IBA will start recognizing
revenue once the final agreement is executed.
Olivier Legrain, Chief Executive Officer
of IBA, commented: “As we have highlighted previously, the
US is of key strategic importance for our business overall and this
latest agreement reinforces our leading position in this market,
being our 17th proton therapy system there. The agreement also
includes both proton therapy and dosimetry elements, demonstrating
the strong synergies between these two business divisions. We look
forward to supporting Advocate Radiation Oncology’s world-class
practice in providing cancer patients with access to the most
advanced radiotherapy technology.”
Dr. Arie Dosoretz, Managing Partner at
Advocate Radiation Oncology, added: “At
Advocate Radiation Oncology, our driving purpose and passion is to
provide the most innovative radiation therapy available to the
patients who need our help. Exploiting the capabilities of advanced
proton therapy is the logical next step in our mission to lead the
fight against cancer. We know that IBA’s experience and industry
leading technology makes IBA’s Proteus®ONE the
clear choice for this endeavor. We are excited to bring a beacon of
hope to our community.”
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is a global
medical technology company focused on bringing integrated and
innovative solutions for the diagnosis and treatment of cancer. The
company is the worldwide technology leader in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA’s proton therapy solutions are
flexible and adaptable, allowing customers to choose from universal
full-scale proton therapy centers as well as compact, single room
solutions. In addition, IBA also has a radiation dosimetry business
and develops particle accelerators for the medical world and
industry. Headquartered in Belgium and employing about 1,500 people
worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange
NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
About Advocate Radiation Oncology
Advocate Radiation Oncology is a locally
owned practice with convenient locations in South Florida. The
practice’s mission is to provide compassionate health care
expertise to cancer patients. Advocate Radiation Oncology
is directed by a team
of world-class, board-certified radiation oncologists,For
more information, please visit AdvocateRO.com.
CONTACTS
Soumya ChandramouliChief
Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Direcor+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
1 Proteus®ONE is the brand name of Proteus®235
- 20210407-IBA-Advocate-RO-EN-final
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Ion Beam Applications (EU:IBAB)
Historical Stock Chart
Von Mär 2023 bis Mär 2024